MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH

The site focuses on rheumatoid arthritis, exploring new treatment options and comparing existing biologic and small‑molecule therapies to improve disease control.

• Long‑term safety of bimekizumab and upadacitinib
• Head‑to‑head efficacy of abatacept versus adalimumab
• Impact of novel TNFR1 inhibitor SAR441566

Investigators at MVZ Rheumatologie und Autoimmunmedizin Hamburg collaborate with pharmaceutical partners to bring innovative options to patients in Hamburg.

Research at the center includes extensive work on psoriatic arthritis, aiming to assess the effectiveness of emerging IL‑17 and JAK inhibitors as well as combination strategies.

• Evaluation of bimekizumab and risankizumab in biologic‑naïve patients
• Dose‑finding studies of sonelokimab and zasocitinib
• Comparative trials of deucravacitinib versus placebo

The program supports patients with active disease who have not responded adequately to conventional DMARDs.

The facility conducts dedicated trials on Sjögren’s syndrome, targeting both systemic disease activity and patient‑reported symptom burden.

• Phase 2 evaluation of HZN‑1116 on systemic manifestations
• Assessment of efgartigimod PH20 and abiprubart for symptom relief
• Investigation of dazodalibep’s effect on ESSDAI scores

These studies aim to expand therapeutic choices for individuals suffering from dry‑eye and glandular dysfunction.

Investigations into axial spondyloarthritis seek to determine long‑term safety of IL‑17 blockade and novel oral agents.

• Extended safety monitoring of bimekizumab in active disease
• Phase 2 trial of tulisokibart assessing ASAS 40 response
• Exploration of JNJ‑88545223 efficacy in radiographic disease

The research contributes to improved management of spinal inflammation and functional limitation.

The center addresses osteoarthritis and related metabolic conditions, testing agents that may reduce joint pain while influencing body weight.

• Orforglipron study measuring WOMAC pain and weight change
• Eloralintide trial focusing on knee pain in overweight participants
• Evaluation of lifestyle‑linked outcomes alongside pharmacotherapy

Findings aim to provide integrated solutions for patients with joint degeneration and obesity.

Trials at the site include investigation of cardiovascular risk in patients with elevated lipoprotein(a).

• Muvalaplin study assessing major adverse cardiovascular events
• Exploratory analysis of ASCVD prevention strategies
• Safety profiling of novel antibodies targeting Lp(a)

Results are expected to inform prevention approaches for high‑risk individuals.

A focused program evaluates disease‑modifying candidates for early symptomatic Alzheimer’s disease.

• Trontinemab trial measuring clinical progression at 72 weeks
• Biomarker assessments to track cognitive decline
• Safety monitoring in participants with mild cognitive impairment

The work supports the search for therapies that could slow or halt disease advancement.

The institution participates in prophylactic research against COVID‑19, evaluating novel monoclonal antibodies.

• AZD3152 and EVUSHELD comparison for symptomatic infection prevention
• Safety cohort assessing AZD5156 tolerability
• Variant‑specific efficacy analyses

These investigations aim to protect vulnerable patients, including those with rheumatic diseases.